Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
2.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
4.
5.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ.

Surg Infect (Larchmt). 2013 Apr;14(2):203-8. doi: 10.1089/sur.2012.034. Epub 2013 Mar 29.

PMID:
23540793
6.

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Cantón R, Paterson DL.

Int J Antimicrob Agents. 2013 Mar;41(3):224-8. doi: 10.1016/j.ijantimicag.2012.10.014. Epub 2013 Jan 8.

PMID:
23305657
7.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.

J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.

PMID:
22546718
8.

Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.

Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC.

Int J Antimicrob Agents. 2012 Jun;39(6):490-5. doi: 10.1016/j.ijantimicag.2012.02.018. Epub 2012 Apr 23.

PMID:
22534507
9.

Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).

Hawser SP, Lob S, Hoban D, Bouchillon S, Badal R.

J Infect. 2012 Jun;64(6):620-2. doi: 10.1016/j.jinf.2012.02.002. Epub 2012 Feb 8. No abstract available.

PMID:
22326560
10.

Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.

Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, Hawser SP, Badal RE, Bonomo RA.

J Clin Microbiol. 2012 May;50(5):1632-9. doi: 10.1128/JCM.06115-11. Epub 2012 Feb 8.

11.
12.

Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates.

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Woodford N, Livermore DM.

Antimicrob Agents Chemother. 2011 Aug;55(8):3917-21. doi: 10.1128/AAC.00070-11. Epub 2011 Jun 13.

13.

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Cantón R.

Clin Microbiol Infect. 2012 Mar;18(3):253-9. doi: 10.1111/j.1469-0691.2011.03550.x. Epub 2011 Jun 2.

14.

Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).

Hawser SP.

Int J Antimicrob Agents. 2011 Aug;38(2):186-7. doi: 10.1016/j.ijantimicag.2011.04.008. Epub 2011 May 31. No abstract available.

PMID:
21632217
15.

Superior activity of colistin against Pseudomonas aeruginosa clinical isolates, including multidrug-resistant isolates, from multiple infection sources from 2007 to 2009.

Hawser SP.

Int J Antimicrob Agents. 2011 Jun;37(6):587. doi: 10.1016/j.ijantimicag.2011.02.011. Epub 2011 Apr 13. No abstract available.

PMID:
21493045
16.

Activity of ertapenem and comparators against recent clinical isolates from intra-abdominal abscesses (SMART 2009).

Hawser SP.

J Infect. 2011 Jun;62(6):496-7. doi: 10.1016/j.jinf.2011.03.008. Epub 2011 Mar 31. No abstract available.

PMID:
21458487
17.

Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL.

J Infect. 2011 Apr;62(4):280-91. doi: 10.1016/j.jinf.2011.02.009. Epub 2011 Mar 5.

PMID:
21382411
18.

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.

Int J Antimicrob Agents. 2011 Mar;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. Epub 2011 Jan 15.

PMID:
21239146
19.

Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL; 2008 Asia–Pacific SMART Group.

Int J Antimicrob Agents. 2010 Nov;36(5):408-14. doi: 10.1016/j.ijantimicag.2010.07.002. Epub 2010 Aug 21.

PMID:
20728316
21.

Susceptibility of Klebsiella pneumoniae clinical isolates from 2007 to 2009 to colistin and comparator antibiotics.

Hawser SP.

Int J Antimicrob Agents. 2010 Oct;36(4):383-4. doi: 10.1016/j.ijantimicag.2010.06.004. Epub 2010 Jul 31. No abstract available.

PMID:
20674285
22.

Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR.

Int J Antimicrob Agents. 2010 Sep;36(3):293-4. doi: 10.1016/j.ijantimicag.2010.05.012. Epub 2010 Jul 3. No abstract available.

PMID:
20598511
23.

In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii.

Hawser SP, Hackel M, Person MB, Higgins PG, Seifert H, Dowzicky M.

Int J Antimicrob Agents. 2010 Sep;36(3):289-90. doi: 10.1016/j.ijantimicag.2010.04.009. Epub 2010 Jun 16. No abstract available.

PMID:
20558046
24.

Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ; SMART India Working Group.

J Med Microbiol. 2010 Sep;59(Pt 9):1050-4. doi: 10.1099/jmm.0.020784-0. Epub 2010 Jun 10.

PMID:
20538892
25.

Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe.

Hawser SP.

Eur J Clin Microbiol Infect Dis. 2010 Aug;29(8):1011-3. doi: 10.1007/s10096-010-0962-7. Epub 2010 May 23.

PMID:
20496091
26.

Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J.

Antimicrob Agents Chemother. 2010 Jul;54(7):3031-4. doi: 10.1128/AAC.01808-09. Epub 2010 May 10.

28.

Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009.

Hawser SP.

J Infect. 2010 May;60(5):401-2. doi: 10.1016/j.jinf.2010.03.001. Epub 2010 Mar 6. No abstract available.

PMID:
20211200
29.

Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).

Hawser SP.

J Infect. 2010 Apr;60(4):306-8. doi: 10.1016/j.jinf.2010.02.003. Epub 2010 Feb 8. No abstract available.

PMID:
20144899
30.

Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.

Hawser SP.

Int J Antimicrob Agents. 2010 Apr;35(4):414-5. doi: 10.1016/j.ijantimicag.2009.11.023. No abstract available.

PMID:
20137900
31.

Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenem susceptibility.

Hawser SP, Hackel M, Hoban DJ.

J Antimicrob Chemother. 2010 Apr;65(4):803-4. doi: 10.1093/jac/dkq016. Epub 2010 Feb 3. No abstract available.

PMID:
20130025
32.

Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp. from Europe.

Hawser SP.

Int J Antimicrob Agents. 2010 Mar;35(3):310-1. doi: 10.1016/j.ijantimicag.2009.11.006. Epub 2009 Dec 31. No abstract available.

PMID:
20045291
33.

Activity of tigecycline against recent European clinical isolates of Clostridium difficile.

Hawser SP.

Int J Antimicrob Agents. 2010 Jan;35(1):97-8. doi: 10.1016/j.ijantimicag.2009.09.009. Epub 2009 Nov 4. No abstract available.

PMID:
19892528
34.

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE.

Int J Antimicrob Agents. 2009 Dec;34(6):585-8. doi: 10.1016/j.ijantimicag.2009.07.013. Epub 2009 Sep 11.

PMID:
19748234
35.

Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.

Hoban DJ, Bouchillon SK, Hawser SP, Badal RE.

Diagn Microbiol Infect Dis. 2010 Jan;66(1):78-86. doi: 10.1016/j.diagmicrobio.2009.06.009. Epub 2009 Sep 5.

PMID:
19733993
36.

Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece.

Hawser SP, Bouchillon SK, Hoban DJ, Hackel M, Johnson JL, Badal RE.

Int J Antimicrob Agents. 2009 Oct;34(4):384-5. doi: 10.1016/j.ijantimicag.2009.05.010. Epub 2009 Jun 27. No abstract available.

PMID:
19560904
37.

Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3280-4. doi: 10.1128/AAC.00426-09. Epub 2009 Jun 8.

38.

MSI-78 Magainin Pharmaceuticals.

Islam K, Hawser SP.

IDrugs. 1998 Sep;1(5):605-9.

PMID:
18465601
39.

Antibacterial drug discovery and development--SRI's 11th Annual Summit.

Hawser SP.

IDrugs. 2006 Jun;9(6):390-3. No abstract available.

PMID:
16752304
41.
42.

Aspirochlorine: a highly selective and potent inhibitor of fungal protein synthesis.

Monti F, Ripamonti F, Hawser SP, Islam K.

J Antibiot (Tokyo). 1999 Mar;52(3):311-8.

44.

Production of extracellular matrix by Candida albicans biofilms.

Hawser SP, Baillie GS, Douglas LJ.

J Med Microbiol. 1998 Mar;47(3):253-6.

PMID:
9511830
45.
46.

Resistance of Candida albicans biofilms to antifungal agents in vitro.

Hawser SP, Douglas LJ.

Antimicrob Agents Chemother. 1995 Sep;39(9):2128-31.

47.
48.

A neurotoxic factor associated with the bloom-forming cyanobacterium Trichodesmium.

Hawser SP, Codd GA, Capone DG, Carpenter EJ.

Toxicon. 1991;29(3):277-8. No abstract available.

PMID:
1904659

Supplemental Content

Loading ...
Support Center